This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.
Original paper

Apixaban for treatment of embolic stroke of undetermined source (ATTICUS randomized trial): Rationale and study design

Volume: 12, Issue: 9, Pages: 985 - 990
Published: Nov 23, 2016
Abstract
Rationale Optimal secondary prevention of embolic stroke of undetermined source is not established. The current standard in these patients is acetylsalicylic acid, despite high prevalence of yet undetected paroxysmal atrial fibrillation. Aim The ATTICUS randomized trial is designed to determine whether the factor Xa inhibitor apixaban administered within 7 days after embolic stroke of undetermined source, is superior to acetylsalicylic acid for...
Paper Details
Title
Apixaban for treatment of embolic stroke of undetermined source (ATTICUS randomized trial): Rationale and study design
Published Date
Nov 23, 2016
Volume
12
Issue
9
Pages
985 - 990
© 2025 Pluto Labs All rights reserved.
Step 1. Scroll down for details & analytics related to the paper.
Discover a range of citation analytics, paper references, a list of cited papers, and more.